NTRK2 Gene

Migration, Crosslink

📖

NTRK2 Gene

active

wiki page Created: 2026-04-02T07:19:25 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-ntrk2

📖 Wiki Page

gene2414 wordssynced 2026-04-02

NTRK2 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">NTRK2 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>NTRK2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Neurotrophic Receptor Tyrosine Kinase 2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>9q22.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>4915</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000148018</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q16620</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>600456</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">BDNF mimetics</td>
<td>Research</td>
</tr>
<tr>
<td class="label">TrkB agonists</td>
<td>Clinical trials</td>
</tr>
<tr>
<td class="label">TrkB modulators</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Exercise therapy</td>
<td>Proven</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT01703091</td>
<td>Phase I/II</td>
</tr>
<tr>
<td class="label">NCT02145628</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">NCT05343728</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">NCT05552369</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label"

...

NTRK2 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">NTRK2 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>NTRK2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Neurotrophic Receptor Tyrosine Kinase 2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>9q22.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>4915</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000148018</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q16620</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>600456</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">BDNF mimetics</td>
<td>Research</td>
</tr>
<tr>
<td class="label">TrkB agonists</td>
<td>Clinical trials</td>
</tr>
<tr>
<td class="label">TrkB modulators</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Exercise therapy</td>
<td>Proven</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT01703091</td>
<td>Phase I/II</td>
</tr>
<tr>
<td class="label">NCT02145628</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">NCT05343728</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">NCT05552369</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">NCT04833161</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">SNP</td>
<td>Location</td>
</tr>
<tr>
<td class="label">rs6265</td>
<td>Val66Met</td>
</tr>
<tr>
<td class="label">rs2289656</td>
<td>Promoter</td>
</tr>
<tr>
<td class="label">rs1867283</td>
<td>Intron</td>
</tr>
<tr>
<td class="label">rs1659412</td>
<td>3'UTR</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Knockout mice</td>
<td>Complete gene loss</td>
</tr>
<tr>
<td class="label">Conditional KO</td>
<td>Tissue-specific</td>
</tr>
<tr>
<td class="label">Transgenic</td>
<td>overexpression</td>
</tr>
<tr>
<td class="label">iPSC neurons</td>
<td>Human context</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's disease</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a>, <a href="/wiki/glioblastoma" style="color:#ef9a9a">Glioblastoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">77 edges</a></td>
</tr>
</table>

Ntrk2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

NTRK2 (Neurotrophic Receptor Tyrosine Kinase 2) encodes the BDNF (brain-derived neurotrophic factor) receptor, also known as TrkB. This receptor tyrosine kinase is essential for synaptic plasticity, learning, memory, and neuronal survival. NTRK2 is a major therapeutic target for depression, Alzheimer's disease, and neurodegenerative disorders.

Gene Information

Protein Structure and Mechanism

Receptor Architecture

TrkB is a transmembrane receptor tyrosine kinase with distinct structural domains[@huang2001]:

Extracellular domain: Contains leucine-rich repeats (LRR) and immunoglobulin-like domains for ligand binding
Transmembrane domain: Single pass helix anchoring the receptor in the lipid bilayer
Cytoplasmic domain: Tyrosine kinase domain that phosphorylates downstream signaling proteins

Activation Mechanism

BDNF binding triggers TrkB dimerization and autophosphorylation:

BDNF binds to the extracellular domain, inducing receptor dimerization

Kinase domain activation leads to autophosphorylation of tyrosine residues

Phosphotyrosine residues serve as docking sites for downstream signaling proteins

Activation of PI3K/Akt, MAPK/ERK, and PLCγ pathways

Isoform-Specific Functions

TrkB.FL (full-length): Contains the tyrosine kinase domain, mediates all known TrkB signaling
TrkB.T1: Truncated isoform lacking the kinase domain, may act as a dominant-negative regulator
TrkB.T2: Another truncated variant with distinct tissue distribution

Normal Function

BDNF receptor: High-affinity binding to BDNF and NT-4/5
Synaptic plasticity: [Long-term potentiation](/mechanisms/long-term-potentiation) (LTP), dendritic spine formation
Learning and memory: Critical for [hippocampus](/brain-regions/hippocampus)-dependent memory
Neuronal survival: Activates PI3K/Akt, MAPK/ERK, and PLCγ pathways
Axonal guidance: Role in development and regeneration

Signaling Pathways

TrkB activates three major downstream signaling cascades upon BDNF binding:

Mermaid diagram (expand to render)

PI3K/Akt Pathway

The PI3K/Akt pathway is the primary pro-survival signaling cascade activated by TrkB[@huang2001]:

Activation of Akt promotes cell survival through phosphorylation of Bad
mTOR activation leads to protein synthesis and synaptic plasticity
Akt also inhibits glycogen synthase kinase-3 beta (GSK3β), reducing tau phosphorylation

MAPK/ERK Pathway

The Ras/MEK/ERK pathway regulates[@minichiello2009]:

Neuronal differentiation during development
Synaptic plasticity and LTP formation
Activity-dependent gene expression

PLCγ Pathway

Phospholipase C-gamma (PLCγ) activation leads to[@poo2001]:

Increased intracellular calcium
Activation of PKC isoforms
Modulation of synaptic transmission

Disease Associations

Alzheimer's Disease

BDNF/TrkB signaling is critically impaired in Alzheimer's disease[@allen2013][@zhou2016]:

Synaptic loss: BDNF/TrkB signaling is essential for synaptic plasticity, and reduced TrkB expression in AD hippocampus contributes to synaptic dysfunction
Amyloid interaction: Amyloid-beta oligomers disrupt BDNF signaling, creating a vicious cycle of neurodegeneration
Tau phosphorylation: Impaired TrkB signaling leads to dysregulated GSK3β activity, increasing tau pathology
Cognitive decline: Reduced TrkB activation correlates with cognitive decline in AD patients

Therapeutic strategies:

AAV-mediated BDNF delivery to restore TrkB signaling[@liu2015]
Small molecule TrkB agonists and BDNF mimetics[@bishop2010]
Exercise and environmental enrichment to increase endogenous BDNF

Parkinson's Disease

BDNF supports dopaminergic neuron survival through NTRK2 signaling[@twardziok2019]:

Dopaminergic protection: TrkB activation protects substantia nigra pars compacta neurons from degeneration
Axonal maintenance: BDNF/TrkB signaling maintains dopaminergic terminals in the striatum
α-synuclein interaction: TrkB signaling can protect neurons from α-synuclein toxicity
Therapeutic approaches: AAV-BDNF/TrkB gene therapy approaches being investigated

Depression and Anxiety

The BDNF/TrkB pathway is a key mediator of antidepressant efficacy[@saarelainen2000][@autry2012]:

Antidepressant action: Most antidepressant treatments increase BDNF expression and TrkB signaling
Rapid-acting antidepressants: Ketamine's rapid antidepressant effects are mediated through TrkB activation
Genetic variants: NTRK2 polymorphisms associated with treatment response and depression risk

Other Diseases

Rett syndrome: NTRK2 dysregulation contributes to neurological deficits
Huntington's Disease: BDNF/TrkB signaling deficit contributes to striatal neuron degeneration
Epilepsy: Altered TrkB expression in epileptic tissue
Various psychiatric disorders: TrkB signaling alterations in depression, anxiety, and PTSD

Expression

Brain Region Distribution

TrkB exhibits region-specific expression throughout the brain[@huang2001]:

Hippocampus: High expression in CA1-CA3 pyramidal neurons and dentate gyrus granule cells
Cortex: Strong expression in layers II-III and V pyramidal neurons
Basal ganglia: Moderate expression in striatum and substantia nigra pars compacta
Cerebellum: Expression in Purkinje cells and granule cells
Amygdala: Variable expression depending on subnucleus

Cellular Expression

TrkB is expressed in multiple cell types[@carvajal2008]:

Neurons: Pyramidal neurons, GABAergic interneurons, dopaminergic neurons
Astrocytes: Moderate TrkB expression, may participate in astrocyte-neuron signaling
Microglia: Low-level expression, BDNF may modulate microglial activity
Oligodendrocytes: Expression in mature oligodendrocytes, supports myelination

Subcellular Localization

Synaptic membranes: Highest density at postsynaptic densities
Dendritic compartments: Concentrated in dendritic shafts and spines
Endosomes: TrkB internalization and recycling through endosomal compartments
Nucleus: Some evidence for nuclear TrkB signaling

Therapeutic Targeting

Cellular and Circuit-Level Effects

Synaptic Plasticity

TrkB signaling is essential for multiple forms of synaptic plasticity[@carvajal2008]:

Long-term potentiation (LTP): BDNF/TrkB signaling is required for LTP induction in the hippocampus
Dendritic spine formation: TrkB activation promotes the growth and maintenance of dendritic spines
Synaptic vesicle trafficking: TrkB signaling modulates presynaptic release probability
Homeostatic plasticity: TrkB mediates activity-dependent synaptic scaling

Neuronal Survival Mechanisms

The PI3K/Akt pathway activated by TrkB promotes neuronal survival through:

Bad phosphorylation: Akt phosphorylates Bad, preventing it from inducing apoptosis
Bcl-2 upregulation: TrkB signaling increases expression of anti-apoptotic Bcl-2 proteins
Caspase inhibition: Akt activity inhibits caspase-9 and caspase-3 activation
mTOR activation: Promotes protein synthesis required for neuronal health

Neurogenesis

TrkB signaling supports hippocampal neurogenesis:

Neural progenitor cell survival: BDNF promotes proliferation and differentiation
Dendritic development: TrkB signaling guides neuronal morphology
Integration: Supports functional integration of new neurons into hippocampal circuits

TrkB Agonists in Development

Several TrkB-targeting therapeutics are in development[@kumar2020]:

7,8-Dihydroxyflavone (7,8-DHF): A small molecule TrkB agonist that crosses the blood-brain barrier
Tropomyosin receptor kinase B agonists: Various pharmaceutical companies developing oral TrkB activators
AAV2-BDNF: Gene therapy delivering BDNF to specific brain regions
TrkB-directed antibodies: Agonist antibodies targeting TrkB

Clinical Trials

NCT01703091: Brain-derived neurotrophic factor (BDNF) for Alzheimer's disease
NCT02145628: AAV-BDNF for Parkinson's disease
Various trials investigating TrkB modulators for depression and anxiety

Genetic Variants

Common Polymorphisms

The NTRK2 gene has several common polymorphisms that may affect disease risk:

Val66Met (rs6265): Located in the BDNF coding region, affects activity-dependent BDNF secretion
NTRK2 variants: Various promoter and coding variants associated with neurological phenotypes

Disease-Associated Mutations

Rare NTRK2 mutations have been linked to:

Hyperphagic syndrome: Early-onset obesity
Neurodevelopmental disorders: Developmental delay, intellectual disability
Psychiatric conditions: Increased susceptibility to depression and anxiety

Future Research Directions

Emerging Therapeutic Approaches

Research continues to advance TrkB-based therapeutics:

Phosphoramidate prodrugs: Novel BDNF mimetics with improved brain penetration
Allosteric modulators: Positive allosteric modulators that enhance BDNF/TrkB signaling without direct receptor activation
Cell-specific targeting: AAV vectors with neuron-specific promoters for targeted BDNF expression
Combination therapies: BDNF/TrkB targeting combined with amyloid or tau-targeted approaches

Biomarker Development

Biomarkers for TrkB pathway activity include:

BDNF levels: Peripheral BDNF as a proxy for central nervous system activity
Phospho-TrkB: Direct measurement of activated TrkB in cerebrospinal fluid
Transcriptional markers: Downstream gene expression signatures

Circuit-Specific Effects

Understanding how TrkB signaling differentially affects specific neural circuits:

Hippocampal circuits: Memory formation and pattern separation
Cortical circuits: Sensory processing and integration
Basal ganglia circuits: Motor learning and habit formation
Limbic circuits: Emotional regulation and mood

Clinical Trials and Therapeutic Development

Active and Recent Clinical Trials

Therapeutic Approaches

Small Molecule Agonists:

7,8-Dihydroxyflavone (7,8-DHF): First-in-class TrkB agonist that crosses the BBB
Tropomyosin receptor kinase B agonists: Pharmaceutical development ongoing
R13 and related compounds: Phosphoramidate prodrugs of BDNF

Gene Therapy:

AAV2-BDNF: Adeno-associated virus-mediated BDNF delivery
AAV-TrkB: Direct TrkB overexpression
Lenti-BDNF: Lentiviral approaches for sustained expression

Biologic Approaches:

TrkB agonist antibodies: Monoclonal antibodies activating TrkB
BDNF mimetics: Engineered protein constructs
Cell therapy: Stem cell-based BDNF delivery

Challenges and Solutions

Short half-life of BDNF: Addressed through viral vectors and stabilized proteins

Blood-brain barrier: AAV delivery and small molecule approaches

Peripheral toxicity: Targeted CNS delivery with AAV vectors

Dosage optimization: Biomarker-guided dosing strategies

Mechanism of Action in Neurodegeneration

Synaptic Protection

TrkB signaling protects synapses through multiple mechanisms:

Mermaid diagram (expand to render)

Axonal Maintenance

TrkB supports axonal health through:

Cytoskeletal stabilization: Regulation of tubulin and actin dynamics
Axonal transport: Enhancement of molecular motor function
Myelin maintenance: Support of oligodendrocyte function

Genetic Factors

NTRK2 Polymorphisms

Rare Mutations

De novo mutations: Associated with developmental disorders
Loss-of-function: Reduced TrkB signaling
Gain-of-function: Constitutive activation

Biomarkers and Diagnostics

Fluid Biomarkers

Serum BDNF: Peripheral marker, correlates with CNS activity
CSF BDNF: Direct CNS measurement
Phospho-TrkB: Activated receptor detection
TrkB ectodomain: Soluble receptor fragment

Imaging Biomarkers

PET tracers: TrkB visualization in development
MRI: Functional connectivity changes
SPECT: Receptor density mapping

Clinical Assessments

Cognitive testing: MMSE, MoCA for AD
Motor scoring: UPDRS for PD
Mood assessments: Depression rating scales

Comparative Biology

Species Conservation

Rodent TrkB: High conservation with human (>95%)
zebrafish models: Developmental studies
Non-human primates: Preclinical validation

Model Systems

Future Directions

Emerging Research Areas

Combination therapies: TrkB activation with amyloid/tau targeting

Precision medicine: Genetic stratification for treatment response

Biomarker-driven trials: Patient enrichment strategies

Novel delivery methods: Exosomes, focused ultrasound

Unmet Needs

Efficient BBB penetration: Critical challenge
Sustained activation: Long-term dosing issues
Biomarker development: Patient selection
Disease modification: Demonstrating slowing of progression

References

[Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function (2001)](https://pubmed.ncbi.nlm.nih.gov/11747827/). Annu Rev Neurosci. 2001;24:677-736.

[Poo MM. Neurotrophins as synaptic modulators (2001)](https://pubmed.ncbi.nlm.nih.gov/11212157/). Nat Rev Neurosci. 2001;2(1):24-32.

[Lu B, et al. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases (2013)](https://pubmed.ncbi.nlm.nih.gov/23685773/). Nat Rev Neurosci. 2013;14(6):401-416.

[Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders (2012)](https://pubmed.ncbi.nlm.nih.gov/22441914/). Pharmacol Rev. 2012;64(2):238-258.

[Murer MG, et al. Brain-derived neurotrophic factor in neurodegenerative diseases (2001)](https://pubmed.ncbi.nlm.nih.gov/11516551/). J Neurol Sci. 2001;191(1-2):21-24.

[Minichiello L. TrkB signalling mechanisms in the brain (2009)](https://pubmed.ncbi.nlm.nih.gov/19686687/). Nat Rev Neurosci. 2009;10(12):850-860.

[Carvajal A, et al. TrkB in the development and plasticity of the mammalian brain (2008)](https://pubmed.ncbi.nlm.nih.gov/18271038/). J Neurosci Res. 2008;86(6):1294-1308.

[Zhou F, et al. BDNF/TrkB signaling-mediated neuroprotection in Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27384040/). CNS Neurol Disord Drug Targets. 2016;15(8):1081-1088.

[Kumar A, et al. Targeting neurotrophin receptors in the aging brain (2020)](https://pubmed.ncbi.nlm.nih.gov/32842523/). Pharmaceuticals. 2020;13(9):260.

[Saarelainen T, et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs (2000)](https://pubmed.ncbi.nlm.nih.gov/11077147/). Neuropharmacology. 2000;39(10):1828-1836.

[Twardziok O, et al. Effectiveness of brain-derived neurotrophic factor in animal models of Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30570768/). J Neural Transm. 2019;126(1):87-100.

[Allen SJ, et al. BDNF: a key therapeutic target for Alzheimer's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23296339/). Nat Rev Neurol. 2013;9(3):131-134.

[Coultas L, et al. TrkB: a novel therapeutic target in neurodegenerative disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20394745/). Exp Neurol. 2010;223(1):94-98.

[Bishop GM, et al. TrkB receptor agonists as potential disease-modifying therapies for Alzheimer's disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20176148/). Neurodegener Dis. 2010;7(1-3):132-138.

[Liu Y, et al. AAV-mediated BDNF expression improves cognitive deficits in Alzheimer's disease models (2015)](https://pubmed.ncbi.nlm.nih.gov/25557367/). Mol Neurobiol. 2015;51(3):1040-1049.

[Zhang L, et al. Small molecule TrkB agonists for treating neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35089012/). J Med Chem. 2022;65(2):1366-1385.

[Nagahama Y, et al. AAV-BDNF gene therapy for Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33784456/). Mol Ther Methods Clin Dev. 2021;21:205-215.

[Wang J, et al. BDNF Val66Met polymorphism and brain function (2020)](https://pubmed.ncbi.nlm.nih.gov/33068391/). Brain Res Bull. 2020;163:141-152.

[Costa A, et al. TrkB signaling in neurogenesis and neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37098012/). Cell Stem Cell. 2023;30(5):589-604.

[Liu X, et al. 7,8-DHF: a promising TrkB agonist for neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/38010456/). Adv Sci. 2023;10(15):e2203456.

Background

The study of NTRK2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[NCBI Gene: NTRK2](https://www.ncbi.nlm.nih.gov/gene/4915)
[UniProt: Q16620](https://www.uniprot.org/uniprot/Q16620)
[OMIM: NTRK2](https://www.omim.org/entry/600456)
[BDNF and TrkB in Depression](https://www.nature.com/articles/nm.3830)
[TrkB Agonists Clinical Trials](https://clinicaltrials.gov/ct2/results?term=TrkB+agonist)

Pathway Diagram

The following diagram shows the key molecular relationships involving NTRK2 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

NTRK2

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-ntrk2
kg_node_id	NTRK2
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-6e1a194ab7e9
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-ntrk2'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

85%

Debates

0

Incoming

17

Outgoing

19

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

NTRK2 Gene

NTRK2 Gene

Introduction

NTRK2 Gene

Introduction

Overview

Gene Information

Protein Structure and Mechanism

Receptor Architecture

Activation Mechanism

Isoform-Specific Functions

Normal Function

Signaling Pathways

PI3K/Akt Pathway

MAPK/ERK Pathway

PLCγ Pathway

Disease Associations

Alzheimer's Disease

Parkinson's Disease

Depression and Anxiety

Other Diseases

Expression

Brain Region Distribution

Cellular Expression

Subcellular Localization

Therapeutic Targeting

Cellular and Circuit-Level Effects

Synaptic Plasticity

Neuronal Survival Mechanisms

Neurogenesis

TrkB Agonists in Development

Clinical Trials

Genetic Variants

Common Polymorphisms

Disease-Associated Mutations

Future Research Directions

Emerging Therapeutic Approaches

Biomarker Development

Circuit-Specific Effects

Clinical Trials and Therapeutic Development

Active and Recent Clinical Trials

Therapeutic Approaches

Challenges and Solutions

Mechanism of Action in Neurodegeneration

Synaptic Protection

Axonal Maintenance

Genetic Factors

NTRK2 Polymorphisms

Rare Mutations

Biomarkers and Diagnostics

Fluid Biomarkers

Imaging Biomarkers

Clinical Assessments

Comparative Biology

Species Conservation

Model Systems

Future Directions

Emerging Research Areas

Unmet Needs

References

Background

See Also

External Links

Pathway Diagram

💬 Discussion